Cargando…
AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma
BACKGROUND: MicroRNAs, as a class of small, well-conserved, non-coding RNAs, are increasing identified as diagnostic biomarkers in many cancers. The dysregulated microRNA-129 (miR-129) is closely related with tumorigenesis and cancer progression. However, their potential role of miR-129 in prostate...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565597/ http://dx.doi.org/10.21037/tau.2017.s066 |
_version_ | 1783258410864607232 |
---|---|
author | Xu, Song Ge, Jing-Ping Zhang, Zheng-Yu Zhou, Wen-Quan |
author_facet | Xu, Song Ge, Jing-Ping Zhang, Zheng-Yu Zhou, Wen-Quan |
author_sort | Xu, Song |
collection | PubMed |
description | BACKGROUND: MicroRNAs, as a class of small, well-conserved, non-coding RNAs, are increasing identified as diagnostic biomarkers in many cancers. The dysregulated microRNA-129 (miR-129) is closely related with tumorigenesis and cancer progression. However, their potential role of miR-129 in prostate cancer still remains largely elusive. AIM: In this study, we aimed to investigate the evidence of miR-129 as prognostic biomarkers for tumor progression and clinical prognosis in prostate cancer patients. RESULTS: The prostate cancer tissues exhibited a significant reduction in miR-129 expression compared with the paracancerous tissues (P<0.05). The miR-129 expression is negatively correlated with histological grade (P=0.000), high preoperative PSA level (P=0.000), pathological stage (P=0.000), high Gleason score (P=0.000), lymph node metastasis (P=0.002), angiolymphatic invasion (P=0.018), biochemical recurrence (P=0.001). Kaplan-Meier analysis demonstrated that low miR-129 expression level was closely associated with poorer biochemical recurrence (BCR)-free survival. Further analysis indicated that (P=0.000) expression may be and independent prognostic factor for BCR-free survival prostate cancer patients (P=0.000). Overexpression of miR-129 markedly attenuated the prostate cancer cell growth via rescuing the dysregulated cell cycle regulatory protein expression. CONCLUSIONS: Taken together, miR-129 was down-regulated in prostate cancer tissues in prostate cancer patients. It may be considered as a novel independent prognostic biomarker for prostate cancer. Downregulation of Mir-129 plays a critical role in proliferation of prostate cancer. |
format | Online Article Text |
id | pubmed-5565597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-55655972017-09-01 AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma Xu, Song Ge, Jing-Ping Zhang, Zheng-Yu Zhou, Wen-Quan Transl Androl Urol Printed Abstracts BACKGROUND: MicroRNAs, as a class of small, well-conserved, non-coding RNAs, are increasing identified as diagnostic biomarkers in many cancers. The dysregulated microRNA-129 (miR-129) is closely related with tumorigenesis and cancer progression. However, their potential role of miR-129 in prostate cancer still remains largely elusive. AIM: In this study, we aimed to investigate the evidence of miR-129 as prognostic biomarkers for tumor progression and clinical prognosis in prostate cancer patients. RESULTS: The prostate cancer tissues exhibited a significant reduction in miR-129 expression compared with the paracancerous tissues (P<0.05). The miR-129 expression is negatively correlated with histological grade (P=0.000), high preoperative PSA level (P=0.000), pathological stage (P=0.000), high Gleason score (P=0.000), lymph node metastasis (P=0.002), angiolymphatic invasion (P=0.018), biochemical recurrence (P=0.001). Kaplan-Meier analysis demonstrated that low miR-129 expression level was closely associated with poorer biochemical recurrence (BCR)-free survival. Further analysis indicated that (P=0.000) expression may be and independent prognostic factor for BCR-free survival prostate cancer patients (P=0.000). Overexpression of miR-129 markedly attenuated the prostate cancer cell growth via rescuing the dysregulated cell cycle regulatory protein expression. CONCLUSIONS: Taken together, miR-129 was down-regulated in prostate cancer tissues in prostate cancer patients. It may be considered as a novel independent prognostic biomarker for prostate cancer. Downregulation of Mir-129 plays a critical role in proliferation of prostate cancer. AME Publishing Company 2017-08 /pmc/articles/PMC5565597/ http://dx.doi.org/10.21037/tau.2017.s066 Text en 2017 Translational Andrology and Urology. All rights reserved. |
spellingShingle | Printed Abstracts Xu, Song Ge, Jing-Ping Zhang, Zheng-Yu Zhou, Wen-Quan AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
title | AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
title_full | AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
title_fullStr | AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
title_full_unstemmed | AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
title_short | AB066. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
title_sort | ab066. mir-129 predicts prognosis and inhibits cell growth in human prostate carcinoma |
topic | Printed Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565597/ http://dx.doi.org/10.21037/tau.2017.s066 |
work_keys_str_mv | AT xusong ab066mir129predictsprognosisandinhibitscellgrowthinhumanprostatecarcinoma AT gejingping ab066mir129predictsprognosisandinhibitscellgrowthinhumanprostatecarcinoma AT zhangzhengyu ab066mir129predictsprognosisandinhibitscellgrowthinhumanprostatecarcinoma AT zhouwenquan ab066mir129predictsprognosisandinhibitscellgrowthinhumanprostatecarcinoma |